369 related articles for article (PubMed ID: 31475440)
1. Prognostic power of a lipid metabolism gene panel for diffuse gliomas.
Wu F; Zhao Z; Chai RC; Liu YQ; Li GZ; Jiang HY; Jiang T
J Cell Mol Med; 2019 Nov; 23(11):7741-7748. PubMed ID: 31475440
[TBL] [Abstract][Full Text] [Related]
2. A prognostic signature of five pseudogenes for predicting lower-grade gliomas.
Liu B; Liu J; Liu K; Huang H; Li Y; Hu X; Wang K; Cao H; Cheng Q
Biomed Pharmacother; 2019 Sep; 117():109116. PubMed ID: 31247469
[TBL] [Abstract][Full Text] [Related]
3. A five-microRNA signature for individualized prognosis evaluation and radiotherapy guidance in patients with diffuse lower-grade glioma.
Zhang JH; Hou R; Pan Y; Gao Y; Yang Y; Tian W; Zhu YB
J Cell Mol Med; 2020 Jul; 24(13):7504-7514. PubMed ID: 32412186
[TBL] [Abstract][Full Text] [Related]
4. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
[TBL] [Abstract][Full Text] [Related]
5. Identification of a five B cell-associated gene prognostic and predictive signature for advanced glioma patients harboring immunosuppressive subtype preference.
Zhang C; Li J; Wang H; Song SW
Oncotarget; 2016 Nov; 7(45):73971-73983. PubMed ID: 27738332
[TBL] [Abstract][Full Text] [Related]
6. Classifying lower grade glioma cases according to whole genome gene expression.
Chen B; Liang T; Yang P; Wang H; Liu Y; Yang F; You G
Oncotarget; 2016 Nov; 7(45):74031-74042. PubMed ID: 27677590
[TBL] [Abstract][Full Text] [Related]
7. Identification of potential biomarkers related to glioma survival by gene expression profile analysis.
Hsu JB; Chang TH; Lee GA; Lee TY; Chen CY
BMC Med Genomics; 2019 Mar; 11(Suppl 7):34. PubMed ID: 30894197
[TBL] [Abstract][Full Text] [Related]
8. Collagen Type III Alpha 1 chain regulated by GATA-Binding Protein 6 affects Type II IFN response and propanoate metabolism in the recurrence of lower grade glioma.
Huang R; Li Z; Zhu X; Yan P; Song D; Yin H; Hu P; Lin R; Wu S; Meng T; Zhang J; Huang Z
J Cell Mol Med; 2020 Sep; 24(18):10803-10815. PubMed ID: 32757451
[TBL] [Abstract][Full Text] [Related]
9. Identification of an energy metabolism-related signature associated with clinical prognosis in diffuse glioma.
Zhou Z; Huang R; Chai R; Zhou X; Hu Z; Wang W; Chen B; Deng L; Liu Y; Wu F
Aging (Albany NY); 2018 Nov; 10(11):3185-3209. PubMed ID: 30407923
[TBL] [Abstract][Full Text] [Related]
10. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
[TBL] [Abstract][Full Text] [Related]
11. Expression of SREBP2 and cholesterol metabolism related genes in TCGA glioma cohorts.
Li D; Li S; Xue AZ; Smith Callahan LA; Liu Y
Medicine (Baltimore); 2020 Mar; 99(12):e18815. PubMed ID: 32195924
[TBL] [Abstract][Full Text] [Related]
12. Identification of RNA: 5-Methylcytosine Methyltransferases-Related Signature for Predicting Prognosis in Glioma.
Wang P; Wu M; Tu Z; Tao C; Hu Q; Li K; Zhu X; Huang K
Front Oncol; 2020; 10():1119. PubMed ID: 32974125
[No Abstract] [Full Text] [Related]
13. Bioinformatic Profiling Identifies a Fatty Acid Metabolism-Related Gene Risk Signature for Malignancy, Prognosis, and Immune Phenotype of Glioma.
Qi Y; Chen D; Lu Q; Yao Y; Ji C
Dis Markers; 2019; 2019():3917040. PubMed ID: 31885736
[TBL] [Abstract][Full Text] [Related]
14. Identification of Periostin as a Potential Biomarker in Gliomas by Database Mining.
Faried A; Hermanto Y; Tjahjono FP; Valentino A; Arifin MZ
World Neurosurg; 2020 Mar; 135():e137-e163. PubMed ID: 31785437
[TBL] [Abstract][Full Text] [Related]
15. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive profiling identifies a novel signature with robust predictive value and reveals the potential drug resistance mechanism in glioma.
Zeng F; Wang K; Liu X; Zhao Z
Cell Commun Signal; 2020 Jan; 18(1):2. PubMed ID: 31907037
[TBL] [Abstract][Full Text] [Related]
17. Prognostic relevance of genetic alterations in diffuse lower-grade gliomas.
Aoki K; Nakamura H; Suzuki H; Matsuo K; Kataoka K; Shimamura T; Motomura K; Ohka F; Shiina S; Yamamoto T; Nagata Y; Yoshizato T; Mizoguchi M; Abe T; Momii Y; Muragaki Y; Watanabe R; Ito I; Sanada M; Yajima H; Morita N; Takeuchi I; Miyano S; Wakabayashi T; Ogawa S; Natsume A
Neuro Oncol; 2018 Jan; 20(1):66-77. PubMed ID: 29016839
[TBL] [Abstract][Full Text] [Related]
18. Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma.
Cheng W; Li M; Jiang Y; Zhang C; Cai J; Wang K; Wu A
J Neurosurg; 2016 Jul; 125(1):7-16. PubMed ID: 26544773
[TBL] [Abstract][Full Text] [Related]
19. CMTM6 overexpression is associated with molecular and clinical characteristics of malignancy and predicts poor prognosis in gliomas.
Guan X; Zhang C; Zhao J; Sun G; Song Q; Jia W
EBioMedicine; 2018 Sep; 35():233-243. PubMed ID: 30131308
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of a microRNA signature as a novel biomarker in patients with lower-grade gliomas.
Qian Z; Li Y; Fan X; Zhang C; Wang Y; Jiang T; Liu X
J Neurooncol; 2018 Mar; 137(1):127-137. PubMed ID: 29204839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
